Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Porgie Tirebiter,"
The intellectual property, in the personalized medicine space, is more the point. Revenue reports and current news are another issue. I make educated assessments based on the information we do have.
Daniel
For anyone who missed it. Particularly, note the part about the Obama administration's strong support for personalized medicine (and Google for more; it is true.) This is good news for DNAG and other companies that own valuable intellectual property, in the personalized medicine space.
Personalized Medicine on Friday's Mad Money...
http://www.cnbc.com/id/28813740
Excerpt: "Personalized medicine uses everything from height and weight to gene and gene-expression information to treat patients. Celera and Abbott are trying to develop molecular diagnostic products to aid in the process. The two firms recently updated their deal, which should lower Celera’s operating expenses and give the company room to launch products outside the joint venture with Abbott. So even if a merger never happens, Celera might stand on its own as a solid investment."
More here:
http://www.madmoneyrecap.com/madmoney_nightlyrecap_012309_2.htm
Excerpt: "... personalized medicine requires a lot of diagnostic tests... and that is what Celera is working on with Abbott Labs... disease detection, assessing an individuals pre-disposition to certain diseases... monitoring the progression of a disease… and choosing the right therapy…. remember President Obama loves this stuff... because it saves money on health care costs down the line..."
http://www.dnaprint.com/welcome/corporate/
http://www.dnaprint.com/welcome/pipeline/
Daniel
"Porgie Tirebiter,"
What do you expect, after the years and years of blatant manipulation -- including the naked shorting, the painting of the tape, the blatant walking down of the price, and the industrial-scale bashing in multiple forums, by multiple aliases. People have complained about the blatant manipulation on numerous occasions. The SEC doesn't seem to enforce anything. But my conviction is, this stock has enormous real value, which will eventually be reflected in PPS.
Daniel
Fox,
I think there are just some weak hands being shaken out, while the new investors play the waiting game, seeing how cheaply they can buy this stock. (The same game as always.) With my long-term perspective, the short-term moves aren't all that important, anyway. But we are still far above .0002, and personalized medicine is now big news (partly because the Obama administration strongly supports it, but also, as Goldenstone77 referred to yesterday:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=35152224
--
An article released yesterday on personalized health care: "Deloitte Center for Health Solutions found significant opportunities for the adoption of personalized medicine to produce a positive return on investment across key stakeholders in the U.S. health care system."
"Personalized medicine is not a promise of the future; it is fast emerging as the current state in diagnostics and therapeutics," said Terry Hisey, vice chairman and U.S. industry leader for Deloitte LLP's Life Sciences industry group."
http://www.cnbc.com/id/28873350
--
Those who aren't aware of all these things, and the real value of DNAPrint Genomics' intellectual property, aren't likely to be able to estimate DNAG's value correctly. It's an ongoing process, of growing awareness. As they say, "patience is a virtue."
Good luck to all,
Daniel
Do you think the stock got this cheap for no reason? With greater opportunity, generally, comes greater risk. That's where intelligence (and planning, and discipline,) comes in. Evaluating the risk VS potential (and likelihood of) reward. If you want everything nice and shiny, stick with blue chips.
Daniel
pma,
Please read today's posts. It isn't a mystery. For one, Personalized Medicine is now taking off in a huge way.
If you want to sell just when things start getting good, go ahead. That's definitely not my strategy.
Good luck to all,
Daniel
Hello, Ernest,
Short answer: no.
My buy limit orders are still in, but I'm not getting any more fills, because the price is surging, and I decided not to chase it. I already have more than 230 million shares, as a result of aggressively averaging down, and I'm content with my current holdings, as a long term investment in DNAG.
Daniel
That was actually my buying... because I own so many shares, I'm required to file those forms with the SEC.
I notice that, over the last 5 trading days, DNAG share price has risen 300%, and we closed at the day's high, today (another bullish sign.) The close today was 900% higher than the all-time low of .0002 ... My conviction is that this is just the tip of the iceberg.
Good luck to all!
Daniel
I think that, before long, a lot of people will understand why I said I consider this to be the world's most undervalued stock. We shall see!
Daniel
Welcome, Fox! And best of luck!
We'd all be interested in the report of your visit. Current info is always appreciated!
Daniel
DNAG outstanding share count remains unchanged, since at least 11/17/2008. (I just called the registrar to confirm.)
Outstanding shares: 1,294,790,465
Authorized shares: 1,500,000,000
Daniel
Looking good!
That's excellent. Thanks, goldenstone77!
Daniel
I think some of the big news is essentially "hidden in plain sight," and few appear to have noticed, but instead appear to have been fooled by the constant baseless claims from "detractor(s.)" I did notice, which is one of the reasons I've been buying.
For instance, someone has been harping on the fact that an instrument was down in the lab, at DNAG HQ. However, recall that DNAPrint Genomics and Beckman Coulter signed a sales and marketing agreement... DNAPrint's tests can be run by technicians in labs that buy Beckman's SNPStream DNA sequencing equipment.
Google search that brings up news about this:
http://www.google.com/search?hl=en&safe=off&q=beckman+coulter+dnaprint+snpstream
From the phone calls I've made to some of the AncestryByDNA distributors, considering what they've told me, my sense is that some of them have bought SNPStream equipment, and are running their own tests. The last distributor I called used wording that implied that they're running their own tests, but that the tests are the same as DNAPrint Genomics' tests, and based on the DNAPrint Genomics' patents. (A question is, how much revenue is DNAPrint deriving from such activity? I hope we find out, soon.)
Another point... An article came out yesterday, about St. Jude Children's Hospital and their ongoing research into ALL (acute lymphoblastic leukemia.) We know that St. Jude has been a partner of DNAPrint Genomics (see links below.) Perhaps now they also have their own SNPStream equipment, and are able to run DNAPrint's tests on-site. (Another educated guess.)
St. Jude Children's Hospital -- Inherited Gene Variations Linked to ALL Treatment Response
January 27, 2009
http://www.medpagetoday.com/HematologyOncology/Leukemia/12618
Mentions DNAPrint's involvement/partnership with St. Jude Children's Hospital:
Inherited genes linked to toxicity of leukemia therapy
May 11, 2007
http://www.stjude.org/stjude/v/index.jsp?vgnextoid=4a8094255c443110VgnVCM1000001e0215acRCRD&vgnextchannel=253ff58ab53c1110VgnVCM1000001e0215acRCRD
Excerpt: "Other authors of this work include ... Tony Frudakis (DNAPrint Genomics, Sarasota, Fla.)"
[Note: My opinions are my opinions only. Please don't go by my opinions, in making investment decisions. Everyone needs to do their own research and decision-making, etc. etc. etc.]
Good luck to all!
Daniel
Hello Sam, and Christopher,
Thanks! I'm still holding onto all my shares, very tightly. I agree that this is just the beginning.
Good luck to all!
Daniel
It's an increase in awareness. Personalized medicine is an important emerging field. DNAG has a lot going for it, as has been described in detail here, many times. They own significant intellectual property in the personalized medicine space, in addition to their other property (AncestryByDNA, DNAWitness, and various patents and patent applications.) The ultimate value of the intellectual property that DNAPrint Genomics owns, in my opinion, is far greater than what is currently reflected in share price. To say nothing of their talent and expertise, relationships with customers (including crime labs,) and with medical institutions, etc.
Daniel
Wrong. R&D companies are vulnerable in that they need sufficient funding until the income is sufficiently developed (initially, they always lose money, and later, when successful, make money.) Small R&D startups are routinely victimized in exactly the way that Babe describes.
I agree 100% with what Babe said.
Daniel
More likely, it's the personalized medicine thing, which DNAPrint Genomics is deeply involved in, and which was discussed on Friday's Mad Money (a widely watched show on CNBC,) and it was mentioned that the Obama administration is very interested in personalized medicine.
When attention gets focused on an extremely undervalued stock like DNAG, it will often tend to appreciate in price. I think we "ain't seen nothin' yet."
Daniel
chiggah,
Well said!
> The wolves wouldn't be sniffing at the door and circling
> the house unless there was meat inside.
> Coming after your shares or trying to kill the company
> is a good sign.
Daniel
sd3445,
You've got that right. I think the best has yet to come!
Good luck to all!
Daniel
"frogdreaming,"
Good grief. That's pure fantasy, that the landlord called me. That person wasn't at all credible. And even so, he didn't claim that DNAPrint Genomics was behind on the rent! That's your invention.
Daniel
I don't think the MM's are doing this. Investors are buying.
Daniel
goldenstone77,
Many reasons. Just one of which appears to be the Obama administration's interest in Personalized Medicine (a field in which DNAPrint Genomics owns significant intellectual property.) Cramer talked about Personalized Medicine, and the new administration's interest in it, last Friday on Mad Money. That may be a catalyst, but there are many reasons I own this stock.
Daniel
Hi mbmun,
Good timing!
Yes, I'm holding all my shares very tightly. I've still never sold a single DNAG share, and I don't plan to, at these low prices. Even though I could start selling shares for a nice profit, already, I think DNAG remains extremely undervalued. I don't subscribe to the "skydiving from pancakes" mentality, that so many others seem to follow.
Good luck to you, and all of us!
Daniel
"frogdreaming,"
That isn't the case, at all. Firstly, as PL1 reported, he saw them recently (Sarah and a lab worker, anyway,) at DNAG HQ. That was much more recently than "months." Secondly, the caller was not seeking information, but was merely trying to deceive and frighten me out of my shares.
When the caller, in a very unconvincing tone, claimed to "represent an investment group," _and_ in the same breath, claimed to be DNAG's "landlord," any presumed/possible credibility he may have had, at the beginning of the phone call, was gone. His persisting in trying to scare me, repeating himself and essentially pleading for a scare, just drove more nails into the coffin of his nonexistent credibility. The caller was obviously irked that his scare was obviously not working. Also, the entire pretext for his phone call to me, was laughable. The whole phone call was very transparent.
Daniel
Personalized Medicine on Friday's Mad Money...
http://www.cnbc.com/id/28813740
Excerpt:
"Personalized medicine uses everything from height and weight to gene and gene-expression information to treat patients. Celera and Abbott are trying to develop molecular diagnostic products to aid in the process. The two firms recently updated their deal, which should lower Celera’s operating expenses and give the company room to launch products outside the joint venture with Abbott. So even if a merger never happens, Celera might stand on its own as a solid investment."
More here:
http://www.madmoneyrecap.com/madmoney_nightlyrecap_012309_2.htm
Excerpt: "... personalized medicine requires a lot of diagnostic tests… and that is what Celera is working on with Abbott Labs… disease detection, assessing an individuals pre-disposition to certain diseases… monitoring the progression of a disease… and choosing the right therapy…. remember President Obama loves this stuff… because it saves money on health care costs down the line..."
http://www.dnaprint.com/welcome/corporate/
http://www.dnaprint.com/welcome/pipeline/
Christopher,
Good luck to you, too!
I don't usually watch Mad Money, but I happened to notice, Personalized Medicine was a major topic on today's show. It was very positively portrayed, and the Obama administration's interest in it, was mentioned.
Daniel
Great article, PL1. Thanks for posting it.
Actually, I disagree with one point made in the article: I think much of this data is already ready to use in a direct clinical manner, especially in the application of preventive medicine, orthomolecular medicine, etc. One nonprofit organization that provides a lot of free information about such things is the Life Extension Foundation -- www.lef.org . There's more info than that out there, too, but it takes a lot of digging to find it all. There's a lot of resistance to a lot of these things, in many circles, mainly due to money interests and biases -- if it's not taught to a doctor in medical school, he/she may be reluctant to trust it or even to look into it, etc. At least, average doctors seem to be rather backward, in this sense, and in some others. When pharma money interests run the curriculum, it's no wonder we see bias, and lots of useful technology severely under-utilized.
> "Such information is not now and may not ever be ready to use in a direct clinical manner, but that does not mean that it isn't incredibly important information," says Evans.
Daniel
sd3445,
Thank you for posting these links, to the videos. Excellent stuff.
We know that Genelex is on the list of AncestryByDNA distributors, but just to be extra sure that Genelex is, in fact, using DNAPrint Genomics' AncestryByDNA products, I spoke with one of Genelex's consultants (Janine) on the phone, a few minutes ago, and she confirmed that Genelex's ethnicity testing (Ethnicity DNA Testing and European Ethnicity DNA Testing) are DNAPrint Genomics' tests (they are the same tests, and DNAPrint Genomics owns the patents underlying the tests.)
Daniel
Hi sd3445,
Yes, I was aware that Tony is on the board at Genelex. I consider it to be a definite positive.
The Bioserve connection that Sam mentioned, is also very interesting, in my opinion.
Daniel
CaptainD2u,
Is there a link that you can provide? I'd like to see those filings.
Thanks,
Daniel
Interestingly, that chart is misleading, in that it gives the impression that DNAPrint Genomics has more competition in the autosomal testing, than it actually does. Multiple companies that actually use DNAPrint for their testing services, are listed in that chart, as providing "Ancestry Percentage - Autosomal" testing. This misleading factor in the chart(s) is something I noticed back in 2007, and is one more reason I'm bullish on DNAG. They don't have a lot of real competition.
Daniel
Being skeptical is rational and valuable, from an investment perspective. Some things that have been said/claimed go far beyond skepticism, into the realms of conspiracy theorizing and personal attack, though.
As for the infamous sign, I've just sent the company an email, inquiring if it's possible for me to help to resolve this issue, of the sign being on the ground. Perhaps a new sign could be produced, and mounted in an attractive fashion, whether on the building, or on a stake with a frame, or whatever. We'll see.
Daniel
sd3445,
As DNAPrint has stated previously, that is due to the financing pinch, and I think it should come as no surprise.
If/when the funding problem is resolved, it is reasonable to assume the financial reports, etc., will resume normally. It is positive that the company already had income streams, and has obviously drastically cut expenses -- necessary steps to survive in such a financing pinch.
What we've recently learned about the company (from Sarah, and PL1,) is encouraging, in my opinion; the reports of the death of the lab are greatly exaggerated. I'm particularly encouraged by Sarah's statement, that the lab instrument that is down, should be back up and running within a few weeks. What PL1 reports about the lab, and the staffing, is also encouraging. Some people may wish to see the lab fully staffed at this time, but in a financing pinch, that can be suicidal for a company. Cutting costs, in my opinion, is a very responsible thing for the company to have done. I trust they are making sound decisions, in controlling costs while trying to maximize revenues. I may be mistaken, but it's an educated guess, and a gesture consistent with the good faith that I've seen the company consistently act on.
Anyway, my convictions about this company and its stock do not require any particular person(s) to agree with me. I've simply been putting my money where my convictions are, following my established investment strategies. I'm essentially an extreme value investor; I like to buy when practically everyone else is too afraid to buy. This strategy has been paying off well, for me. Of course there is risk, and I do not wish anyone to be unaware of that.
Daniel
"frogdreaming,"
Substantiate your claims if you wish to convince anyone. "It is a scam company run by liars and cheats" is simply an unsubstantiated personal attack against the company's officers and employees, the kind of empty accusation that I consider is worth less than nothing. DNAPrint Genomics is the real deal; there is nothing about the company, its products, its intellectual property, or its experience/expertise, that is remotely a "scam."
Perhaps you are forgetting how many parties consider DNAPrint Genomics and its technologies in a very favorable light.
Google search: DNAPrint cutting edge
http://www.google.com/search?hl=en&q=DNAPrint+cutting+edge&aq=f&oq=
Google News search: DNAPrint cutting edge
http://news.google.com/archivesearch?hl=en&um=1&ie=UTF-8&tab=wn&q=DNAPrint+cutting+edge
There are many other examples, of how highly regarded the company and its technologies, and products, are. Here's one Wired article, that you seem to have forgotten:
The Inconvenient Science of Racial DNA Profiling
By Melba Newsome 10.05.07
http://www.wired.com/science/discoveries/news/2007/10/dnaprint/?currentPage=all
Oh, heck, here's another bone I'll throw to you:
"On the recommendation of DNAPrint, we also excluded samples with 40 or more failed markers"
From:
The population-based National Down Syndrome Project combined
epidemiological and molecular methods to study congenital heart
defects in Down syndrome
March 2008 Vol. 10 No. 3
http://www.genetics.emory.edu/DSC/research/pubs/freeman.pdf
Authors list:
Sallie B. Freeman, PhD1, Lora H. Bean, PhD1, Emily G. Allen, PhD1, Stuart W. Tinker, BS1, Adam E. Locke, BA1,
Charlotte Druschel, MD, MPH2, Charlotte A. Hobbs, MD, PhD3, Paul A. Romitti, PhD4, Marjorie H. Royle, PhD5,
Claudine P. Torfs, PhD6, Kenneth J. Dooley, MD7, and Stephanie L. Sherman, PhD1
It appears some very well qualified people (including the authors listed above) take the advice of DNAPrint Genomics quite seriously. This is not compatible with your claims, "frogdreaming."
The burden of conspiracy claims lies on the person(s) putting forth the claim(s.) Substantiate your claims, or withdraw them.
Daniel
"frogdreaming,"
DNAPrint Genomics is no "sham company." It is, as we very well know, a company that is struggling with financing issues. That does not, in any way, shape, or form, make it a "sham company."
As for the lab instrument that Sarah told me was currently down, she said it should be back up and running within "a few weeks."
What do you expect from microcap research and development stocks, struggling with financing issues? I think DNAG has been extremely reserved in the issuance of new shares, relative to other companies in similar situations. People who buy such stocks only have themselves to blame, if they don't understand the realities surrounding such stocks. Get-rich-quick-with-no-risk dreams are delusional.
In my opinion, DNAPrint Genomics well deserves to succeed. It is gratifying to see that the constant reports of its demise, have been greatly exaggerated. (For some reason, I never see any retractions from the "detractor" aliases, no matter how often they are proven wrong.)
Daniel
PL1,
Thanks for the update! That's good to know... It appears the the negative reports and speculation we've been constantly seeing, have been highly exaggerated.
Have a terrific rest of your day, and a great weekend... thanks again!
Daniel
Incorrect. The good news is that they apparently still have a lab, and lab staff, and that the instrument that is down, is expected to be back up within a few weeks.
FYI, good news is positive news, not some gratuitous straw man argument involving the alleged misinterpretation of negative news.
> Someone has picked up the phone and acknowledged that tests
> are not being performed due to equipment issues. This is
> interpreted as good news.
Daniel
Last time I called the registrar, on Jan. 9 this year, the outstanding share count for DNAG was: 1,294,790,465 (unchanged since 11/17/2008.) The authorized share count remained unchanged, at 1,500,000,000.
Relative to many other stocks trading in the pink sheets, it apears the DNAG share count has been remarkably stable.
Registrar info:
Standard Registrar & Transfer
12528 S 1840 E, Draper, UT 84020-9100, United States
Phone: (801) 571-8844
I wonder why others don't call the registrar, and inquire whenever they wonder what the outstanding share count is. It's easy to do.
To get an idea of just how undervalued this stock is, it's useful to look at the current market cap. (Outstanding shares multiplied by current price per share, for any readers who may not know how to calculate market cap.) At .0005 (today's closing price,) and assuming outstanding shares remain 1,294,790,465 ... market cap is a mere $647,395.23 ... At .0006 (the price at which most of the shares were transacted today,) the market cap is a mere $776,874.28 . When market cap is significantly below actual (or projected) value, the stock is cheap. I've been buying DNAG precisely because I consider it to be cheap (very cheap) ... but certainly not without risk.
Daniel
"frogdreaming,"
You said, "...those stocks involved in questionable practices..." -- what does that insinuation have to do with DNAG? It's easy to insinuate anything in the world. It's a different thing, to substantiate.
Daniel